Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The drug didn’t show any superiority in the ... Verona Pharma's plans to transform COPD treatment with recently approved Ohtuvayre look like they are on course, given early sales figures.

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

Cholinergic drugs (acetylcholine ... asthmatics and in COPD patients with a history of asthma, showing an additional bronchodilator effect on top of the current asthma treatment.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...

You may have COPD if you notice persistent, prolonged changes to your breathing. Symptoms can include: These symptoms usually worsen over time without treatment. You can also develop conditions ...

The Zephyr Valve procedure is a minimally invasive treatment for severe or very severe COPD and emphysema. It offers an alternative to highly invasive options like lung transplants, which carry ...